Open AccessThe use of benazepril in hypertensive patients age 55 and over
Author(s) -
Smith Mcfate W.,
Gomez Hector J.
Publication year - 1991
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960141813
Subject(s) - benazepril , medicine , hydrochlorothiazide , blood pressure , placebo , angiotensin converting enzyme , population , clinical trial , ace inhibitor , cardiology , urology , alternative medicine , environmental health , pathology
Benazepril, a newer angiotensin‐converting enzyme inhibitor, has been evaluated for the treatment of mild to moderate hypertension in patients 55 years of age and older. The results of the clinical trials conducted to date indicate that benazepril provides effective antihypertensive therapy in this population, with efficacy comparable to that demonstrated in younger patients. Benazepril does not produce precipitous decreases in diastolic blood pressure following the initial dose, and is well tolerated by the elderly. It has a safety profile similar to that of placebo and generally better than that of hydrochlorothiazide.